Drugs / INCB053914
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04355039 | Jul 2021 → Jul 2023 | refractory plasma cell neoplasm | Medical College of Wisconsin | Withdrawn | No outcome recorded |
| Phase 1 | NCT03688152 | Dec 2018 → Sep 2020 | diffuse large B-cell lymphoma | Incyte Corporation | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02587598 | Dec 2015 → Aug 2020 | cancer | Incyte Corporation | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INCB053914 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03688152 ↗ |
| Action | Inhibit | “the pan-PIM kinase inhibitor” PMID 37290996 ↗ May 2023 |
| Route | Oral | “INCB053914 tablets to be administered by mouth.” NCT02587598 ↗ |